Evidence for the activity of lamotrigine at 5-HT1A receptors in the mouse forced swimming test

Journal of Psychiatry and Neuroscience

Volumn 30, Issue 4, 2005, Pages 275-282

  Bourin, Michel ^a   Masse, Fabienne ^a   Hascoët, Martine ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 METHOXY 3 (1,2,3,6 TETRAHYDRO 4 PYRIDYL) 1H INDOLE; ANPIRTOLINE; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; PINDOLOL; SEROTONIN 1A RECEPTOR; VALPROIC ACID; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; FOCAL EPILEPSY; FORCED SWIMMING TEST; LIGAND BINDING; MALE; MOUSE; NONHUMAN; RECEPTOR BINDING; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; STIMULUS RESPONSE;

ANIMALS; ANTICONVULSANTS; ANTIMANIC AGENTS; COERCION; MALE; MICE; RECEPTORS, SEROTONIN; SWIMMING; TRIAZINES;

EID: 24144431593     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 1992;13:107-12.
2. Cunningham MO, Jones RSG. The anticonvulsivant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 2000;39:2139-46.
3. Weisler R, Risner ME, Acher J, Houser T. Use of lamotrigine in the treatment of bipolar disorder [abstract]. American Psychiatric Association annual meeting; 1994 May 21-26; Philadelphia.
4. Walden J, Hesslinger BJ, Van Calker D, Berger M. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 1996;29:193-5.
5. Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 2003;23:484-94.
6. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs 2003;63:2029-50.
7. Grunze H, Walden J. Relevance of new and newly rediscovered anticonvulsants for atypical forms of bipolar disorder. J Affect Disord 2002;72 Suppl 1:S15-21.
8. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013-24.
9. Calabrese JR, Vieta E, Sheldon MD. Latest maintenance data on lamotrigine in bipolar disorder. Eur Neuropsychopharmacol 2003;13 Suppl 2:S57-66.
10. Brunet G, Cerlich B, Robert P, Dumas S, Souetre E, Darcourt G. Open trial of a calcium antagonist, nimodipine, in acute mania. Clin Neuropharmacol 1990;13:224-8.
11. Dubovsky S. Calcium antagonists in manic-depressive illness. Neuropsychobiology 1993;27:184-92.
12. Walden J, Fritze J, Van Calker D, Berger M, Grunze H. A calcium antagonist for the treatment of depressive episodes: single case reports. J Psychiatr Res 1995;29:71-6.
13. von Wegerer J, Hesslinger B, Berger M, Walden J. A calcium antagonistic effect of the new antiepileptic drug lamotrigine. Eur Neuropsychopharmacol 1997;7:77-81.
14. 1A receptor mediated response in rat brain. Neurochem Int 2002;40:315-9.
15. 2A, receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry 2004;55:225-33.
16. 1B receptors in the mouse forced swimming test: comparison with carbamazepine and sodium valproate. Psychopharmacology (Berl) 1999;141:370-7.
17. Calabrese JR, Delucchi GA. Phenomenology of rapid cycling manic depression and its treatment with valproate. J Clin Psychiatry 1989;50:30-4.
18. Kramlinger KG, Post RM. The addition of lithium to carbamazepine. Antidepressant efficacy in treatment-resistant depression. Arch Gen Psychiatry 1989;46:794-800.
19. Machado-Vieira R, Kapczinski F, Soares JC. Perspectives for the development of animal models of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:209-24.
20. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-36.
21. 1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur J Pharmacol 1996;318:213-20.
22. 3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol 1997;325:129-35.
23. Redrobe JP, Bourin M. Augmentation of antidepressant pharmacotherapy: a preclinical approach using the forced swimming test. CNS Spectr 1999;4:73-81.
24. 1B/D receptor antagonists and antidepressants in the forced swimming test. Eur J Pharmacol 2004;487:133-42.
25. 1B receptors in the mediation of behavior in the forced swim test in mice. Neuropsychopharmacology 2001;24:391-8.
26. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-51.
27. Artigas F, Celeda P, Lamelle M, Adell A. How does pindolol improve antidepressant action? Trends Pharmacol Sci 2001;22:224-8.
28. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995;15:217-22.
29. 1 recognition site. Eur J Pharmacol 1983;90:151-3.
30. 1A autoreceptor in vivo. Br J Pharmacol 1998;124:206-12.
31. 1A receptor agonist 8-OHDPAT in the rat. Eur J Pharmacol 1992;219:105-12.
32. 1B receptor modulation of RU 24969-induced behavioral profile in rats. Pharmacol Biochem Behav 2002;71:569-80.
33. 1B receptor agonist with antinociceptive/antidepressant-like actions in rodents. Br J Pharmacol 1992;105:732-8.
34. Bourin M, Lambert O, Guitton B. Treatment of acute mania - from clinical trials to recommendations for clinical practice. Hum Psychopharmacol Clin Exp 2005;20:15-26.
35. Boissier JR, Simon P. Action de la caféine sur la motilité spontanée de la souris. Arch Int Pharmacodyn Ther 1965;158:212-21.
36. Rocha FL, Hara C. Lamotrigine augmentation in unipolar depression. Int Clin Psychopharmacol 2003;18:97-9.
37. Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 2002;63:737-41.
38. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607-14.
39. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003;64:403-7.
40. Normann C, Hummel B, Scharer LO, Horn M, Grunze H, Walden J. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry 2002;63:337-44.
41. Szymczyk G, Zebrowska-Lupina I. Influence of antiepileptic on efficacy of antidepressant drugs in forced swimming test. Pol J Pharmacol 2000;52:337-44.
42. Nixon MK, Hascoët M, Bourin M, Colombel M. Additive effect of lithium and antidepressants in the forced swimming test: further evidence for involvement of the serotoninergic system. Psychopharmacology (Berl) 1994;115:59-64.
43. Keck PE, Nelson EB, McElroy SL. Advances in the pharmacologic treatment of bipolar depression. Biol Psychiatry 2003;53:671-9.
44. 1B autoreceptors and heteroreceptors and 5-HT moduline in CNS disorders. CNS Spectr 1998;3:50-8.
45. 1A receptors. Br J Pharmacol 1993;108:669-77.
46. 1A antagonists. Trends Neurosci 1996;19:378-83.
47. 1A receptors in augmenting antidepressant activity in mouse forced swimming test. Psychopharmacology 1998;136:226-34.
48. Leach MJ, Randall AD, Stefani A, Hainsworth AH. Lamotrigine: mechanism of action. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott William & Wilkins; 2002. p. 363-415.
49. Ahmad S, Fowler LJ, Whitton P. Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat. Br J Pharmacol 2004;142:136-42.
50. Southam E, Kirkby D, Higgins GA, Hagan RM. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol 1998;358:19-24.
51. 1A receptor function in healthy human males. J Affect Disord 1998;49:157-62.
52. Bill DJ, Knight M, Forster EA, Fletcher A. Direct evidence for an important species difference in the mechanism of 8-OHDPAT-induced hypothermia. Br J Pharmacol 1991;103:1857-64.
53. Millan MJ, Rivet JM, Canton H, Le Marouille-Girardon S, Gobert A. Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists. J Pharmacol Exp Ther 1993;264:1364-76.
54. 1A receptor-mediated hypothermia in mice: absence of spare receptors and rapid induction of tolerance. Pharmacol Biochem Behav 1992;43:405-11.
55. Bourin M, Lambert O, Guitton B. Treatment of acute mania - from clinical trials to recommendations for clinical practice. Hum Psychopharmacol 2005;20:15-26.